Last reviewed · How we verify
NCT04032795
Evaluation of Efficacy of Lycium Barbarum Polysaccharide in People With Subthreshold Depression
NA trial testing Lycium barbarum polysaccharide in Subthreshold Depression in 172 participants. Status unknown.
30 December 2021
Quick facts
| Lead sponsor | Guangzhou Psychiatric Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 172 |
| Start date | 15 May 2019 |
| Primary completion | 30 December 2021 |
| Estimated completion | 30 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Lycium barbarum polysaccharide
- Placebo
Conditions studied
- Subthreshold Depression — all drugs for Subthreshold Depression →
- Depressive Symptoms — all drugs for Depressive Symptoms →
- Anxious Symptoms — all drugs for Anxious Symptoms →
Sponsor
Guangzhou Psychiatric Hospital
Who can join
Adults 12 to 18, any sex, with Subthreshold Depression or Depressive Symptoms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lycium barbarum, a traditional Chinese herbal medicine, is a commonly used herb in the traditional Chinese pharmacopoeia . Its main active ingredient, lycium barbarum polysaccharide (LBP), is reported to have neuroprotective effects. Animal studies suggested that LBP has neuroprotective effect on optic ganglion cells. In animal models of depression, LBP can improve depressive symptom by improving synaptic plasticity. However, its clinical effect remains to be studied. We will conduct a 6-week double-blind, randomized, placebo-con-trolled trial in people with subthreshold depression.The purpose of this clinical trial is to investigate the efficacy of LBP in people with subthreshold depression.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Efficacy of <i>Lycium barbarum</i> polysaccharide in adolescents with subthreshold depression: interim analysis of a randomized controlled study.
Li X, Mo X, Liu T, Shao R, et al · · 2022 · cited 33× · PMID 34916444 · DOI 10.4103/1673-5374.330618 -
Effects of Lycium barbarum polysaccharide on cytokines in adolescents with subthreshold depression: a randomized controlled study.
Li X, Liu T, Mo X, Wang R, et al · · 2024 · cited 8× · PMID 38227533 · DOI 10.4103/1673-5374.389360
Verify or expand the search:
- PubMed search for NCT04032795
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Lycium barbarum polysaccharide
Trials testing the same drug.
- NCT04124276 — Evaluation of Efficacy of Lycium Barbarum Polysaccharide in Patients With Major Depressive Disorder · NA · unknown
Other recruiting trials for Subthreshold Depression
Currently open trials in the same condition.
- NCT07319143 — The Effect of Transcranial Direct Current Stimulation (tDCS) in Improving Emotion Health · NA · recruiting
Other Guangzhou Psychiatric Hospital trials
Trials by the same sponsor.
- NCT06658795 — Treating Loneliness In The Older Adult With Depression With tDCS · NA · recruiting
- NCT04816617 — The Effect of Exercise on Cognition and Preventing Depression in Young People · NA · completed
- NCT04803071 — Omega-3 Unsaturated Fatty Acid Improves Cognitive Function in Patients With Depression · NA · unknown
- NCT04447430 — Light Therapy to Improve Symptoms in Pregnant Women With Major Depressive Disorder · NA · unknown
- NCT04124276 — Evaluation of Efficacy of Lycium Barbarum Polysaccharide in Patients With Major Depressive Disorder · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04032795 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Psychiatric Hospital
- Last refreshed: 19 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04032795.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing